Mau Ern Poh
Overview
Explore the profile of Mau Ern Poh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poh M, Balakrishnan S, Tan S, Abidin M, Liam C, Tan J, et al.
Transl Lung Cancer Res
. 2024 Aug;
13(7):1649-1659.
PMID: 39118879
Background: Response rates of epidermal growth factor receptor ()-mutated advanced non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) and 40 mg OD] are...
2.
Poh M, Chai C, Liam C, Ho G, Pang Y, Hasbullah H, et al.
Transl Lung Cancer Res
. 2024 Mar;
13(2):307-320.
PMID: 38496703
Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor ()-mutant non-small cell lung cancer...
3.
Mac Aogain M, Ivan F, Jaggi T, Richardson H, Shoemark A, Narayana J, et al.
Am J Respir Crit Care Med
. 2024 Jan;
210(1):47-62.
PMID: 38271608
Chronic infection and inflammation shapes the airway microbiome in bronchiectasis. Utilizing whole-genome shotgun metagenomics to analyze the airway resistome provides insight into interplay between microbes, resistance genes, and clinical outcomes....
4.
Liam C, Yew C, Pang Y, Wong C, Poh M, Tan J, et al.
BMC Cancer
. 2023 Jul;
23(1):659.
PMID: 37452277
Background: In non-small cell lung cancer (NSCLC), there may be a relationship between programmed death-ligand 1 (PD-L1) expression, driver mutations and cigarette smoking. Methods: In this single-center retrospective study, the...
5.
Soo C, Ong D, Chin K, Sia L, Munusamy V, Ibrahim N, et al.
Respirol Case Rep
. 2023 Jun;
11(7):e01181.
PMID: 37350988
Neoadjuvant chemotherapy is a therapeutic option for potentially resectable non-small cell lung cancer (NSCLC). The role of neoadjuvant targeted therapy (NTT) remains less explored. This case highlights the use of...
6.
Poh M, How S, Ho G, Pang Y, Hasbullah H, Tho L, et al.
Cancer Manag Res
. 2023 Jan;
15:31-41.
PMID: 36660237
Purpose: Anaplastic lymphoma kinase (ALK) inhibitors are associated with good overall survival (OS) for ALK-positive metastatic non-small cell lung cancer (NSCLC). However, these treatments can be unavailable or limited by...
7.
Tiew P, Narayana J, Quek M, Ang Y, Ko F, Poh M, et al.
Eur Respir J
. 2022 Aug;
61(1).
PMID: 35926878
Background: Variable clinical outcomes are reported with fungal sensitisation in chronic obstructive pulmonary disease (COPD), and it remains unclear which fungi and what allergens associate with the poorest outcomes. The...
8.
How S, Liam C, Abidin M, Hasbullah H, Tho L, Ho G, et al.
Cancer Manag Res
. 2022 Jun;
14:1995-2005.
PMID: 35733510
Background: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR mutation. The third-generation EGFR-TKI has demonstrated efficacy in...
9.
How S, Tho L, Liam C, Hasbullah H, Ho G, Muhammad Nor I, et al.
Thorac Cancer
. 2022 May;
13(11):1676-1683.
PMID: 35502623
Introduction: Immune checkpoint inhibitor (ICI) therapy is an established treatment for advanced non-small-cell lung cancer (NSCLC) and programmed death ligand-1 (PD-L1) expression is a recognized biomarker to determine response to...
10.
Tiew P, Hou Lim A, Keir H, Dicker A, Mac Aogain M, Pang S, et al.
Chest
. 2021 Aug;
161(1):40-53.
PMID: 34364870
Background: Allergic bronchopulmonary aspergillosis (ABPA) is associated with frequent exacerbations and poor outcomes in chronic respiratory disease, but remains underdiagnosed. The role of fungal sensitization in bronchiectasis-COPD overlap (BCO) is...